551 participants
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2016-05-23
- Start Date:
- 2011-09-30
- Completion:
- 2015-02-28
Conditions
- Rheumatoid Arthritis
Interventions
- BIOLOGICAL